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Abstract: Microparticles (MPs) are small membrane vesicles released by 
stimulated or apoptotic cells, including the endothelium. Hyperhomocysteinemia 
(HHcy) is a blood disorder characterized by an increase in the plasma 
concentrations of total homocysteine (Hcy). The plasma Hcy level is determined 
by environmental factors (dietary habits, i.e. the intake of folic acid, FA) and 
genetic factors (N5,N10-methylenetetrahydro-folate reductase, MTHFR, 
polymorphism 677C>T). To evaluate whether moderate Hcy concentrations 
induce endothelial MP formation, the role of FA supplementation and the 
influence of MTHFR polymorphism were analysed. Human umbilical vein 
endothelial cells (HUVEC) were treated in vitro with 50 μM of Hcy and 
methionine (Met). The MP number and apoptotic phenotype were analyzed 
using flow cytometry. Increasing doses of FA (5, 15 and 50 μM) were used to 
reduce the HHcy effect. The MTHFR 677C>T polymorphism was determined. 
HUVEC stimulated by Hcy produced significantly more MPs than HUVEC 
under the control conditions: 3,551 ± 620 vs 2,270 ± 657 kMP  (p = 0.02). 
Supplementation with FA at concentrations of 5, 15 and 50 μM reduced the MP 
count in the cell culture supernatant to 345 ± 332, 873 ± 329, and 688 ± 453 kMP, 
respectively (p = 0.03). MTHFR 677C>T heterozygosity was associated with  
a significant increase in MP formation after stimulation with Hcy compared to 
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the control conditions: 3,617 ± 152 vs 1,518 ± 343 kMP (p = 0.02). Furthermore, 
the MTHFR genotype altered MP formation after Met loading. On average, 24% 
of the entire MP population was apoptotic (annexin V-positive). Endothelial 
function impairment due to HHcy is related to MP shedding, which may involve 
platelets and other blood and vascular cells. MP shedding is a physiological 
response to moderate HHcy. 
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Homocysteine (Hcy) is a sulphur amino acid synthesized during the metabolic 
conversion of methionine to cysteine. In the trans-sulphuration pathway, 
homocysteine is converted to cystathionine, but it can also be remethylated via 
the folate cycle. This pathway requires the methionine synthase enzyme and 
cobalamin (vitamin B12) as well as the N5,N10-methylenetetrahydrofolate 
reductase enzyme (MTHFR) and folic acid (FA), which enters the cycle as 
tetrahydrofolate [1]. 
Normal Hcy levels oscillate between 5 and 15 μM. Higher concentrations are 
considered to indicate a metabolic disorder called hyperhomocysteinemia 
(HHcy) [1]. While severe HHcy (over 100 μM) is a rare condition, 5 to 7% of 
the general population suffers from mild to moderate hyperhomocysteinemia  
(15 to 100 μM). Numerous epidemiological and clinical studies have indicated 
an association between elevated plasma Hcy concentrations and vascular 
diseases, including coronary artery disease (CAD), stroke, myocardial infarction 
(MI) and venous thromboembolism [2-4]. Plasma Hcy levels are determined by 
demographic, environmental and genetic factors. Normal homocysteine 
metabolism is dependent on an adequate supply of three dietary vitamins:  
FA, vitamin B12 and vitamin B6. Thus, a nutritional deficiency of these vitamins 
may cause moderate HHcy [3, 5]. Several genetically inherited enzyme 
mutations responsible for elevated homocysteine levels have been described, of 
which probably the most common one is the cytosine to thymine transition at 
nucleotide 677 (677C>T) of the MTHFR enzyme [5]. This polymorphism 
decreases MTHFR activity, which is associated with a decrease in the 
redundancy ratio of 5,10-MTHF to 5-MTHF and an increase in the level of  
5,10-MTHF bioavailability for the oxidation of folate to formyl forms [6]. 
Endothelial dysfunction, i.e. impairment of the homeostatic properties of the 
vascular endothelium, leads to adverse cardiovascular outcomes. The 
hyperhomocysteinemic state causes endothelial dysfunction in humans, animals 
and in the experimental in vitro model [7-9]. Endothelial cell activation followed 
by apoptosis is also related to endothelial dysfunction. In this state, endothelial 
cells release qualitatively and quantitatively diverse small membrane vesicles 
called microparticles (MPs), which vary in diameter between 0.1 and 1.5 µm. 




MPs are used as a marker of endothelial dysfunction and the procoagulation 
state [10, 11]. MPs may harbor a diversity of cell surface proteins, among them 
CD31 (PECAM-1, platelet endothelial cell adhesion molecule-1), which is  
a selective marker of matured and progenitor endothelial cells [12]. Additionally, 
phosphatidylserine, which is specifically bound to annexin V, is exposed on the 
endothelial MP surface [12], and annexin V-positive MPs are observed during 
apoptosis [10]. There is little evidence that homocysteine influences MP formation. 
In patients with chronic renal failure, both dialyzed and undialyzed, the elevation 
of apoptotic, annexin V-positive, endothelial MPs was observed [13]. However, 
the role of p-cresol and indoxyl sulfate rather than Hcy was documented [13, 14].  
In our study, we tested the hypothesis that moderate concentrations of 
homocysteine induced the formation of endothelial MPs in vitro and investigated 
whether this activity is regulated by folate supplementation and the MTHFR 
polymorphism. We also tried to determine the phenotype of endothelium-
released microparticles.  
 
MATERIALS AND METHODS 
 
Endothelial cell culture 
Human umbilical vein endothelial cells (HUVEC) were isolated by digestion 
using 0.25% trypsin in Ca2+ free Hanks balanced salt solution (No. 27250018, 
Gibco®). The cells were cultured in 25-cm2 flasks with Human Endothelial 
Serum Free Medium (SFM, 11111044) supplemented with 10% Fetal Bovine 
Serum (FBS, No. 10100139, Gibco®) purchased from Invitrogen (Paisley, UK), 
2 mM of L-glutamine (No. G8540, Sigma-Aldrich, Steinheim, Germany) and 
antibiotics (50 U/ml penicillin, 50 μ/ml streptomycin, 0.1 mg/ml neomycin, 
Polfa Tarchomin, Poland). HUVEC from passages 3-4 after overnight serum 
starvation were used in the study. All of the experiments were performed in 
duplicate, using nine different primary cell lines. 
 
Microparticle formation and isolation 
After reaching full confluence, the HUVEC were treated for 24 h with 50 µM 
DL-Hcy (No. H4628), 5, 15, 50 µM FA (No. F8758) or 50 µM DL-methionine 
(No. M2768) purchased from Sigma-Aldrich (Steinheim, Germany). The cell 
culture supernatant was collected and centrifuged for 15 min at 4,500 g. Then 
the supernatant was centrifuged for 1.5 h at 100,000 g at 4ºC using an 
ultracentrifuge (Avanti J-30I, Beckman Instruments Inc. Fullerton, USA). Next, 
the pellets were resuspended in 500 μl of Binding Buffer (BB, PharmingenTM, 
BD Bioscience, Bedford, USA) and analysed.  
 
Flow cytometry analysis of microparticles 
Microparticle acquisition was performed using a mix of fluorescent beads of 
various diameters to cover the MP size range from 0.5 to 0.9 μm (Megamix, 
Biocytex, France) by means of the FACS Calibur instrument (BD 
Immunocytometry Systems, San Jose, USA). MPs resuspended in BB (50 µl) 
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were incubated in the dark (30 min, 4ºC) with 5 µl of PE-conjugated monoclonal 
antibody against CD31 (PECAM-1) and 5 µl of FITC-conjugated annexin V 
(Annexin V-FITC Apoptosis Detection Kit I, PharmingenTM, BD Bioscience, 
Heilderberg, Germany) and then centrifuged (1.5 h, 100,000 g, 4ºC) [12]. 
Afterwards, the pellets were resuspended in 500 μl of PBS, and flow cytometry 
analysis was performed. The data was analyzed using CellQuest Pro software 
(BD Immunocytometry Systems, San Jose, USA). The MP number was 
calculated according to Brodsky et al. [11]. Then the number of MPs shed by the 
HUVEC was standardized to the number of cells cultured in each flask (kMP). 
 
Hcy analysis 
To control the real Hcy concentration under our experimental conditions, High 
Performance Liquid Chromatography (HPLC) with ultraviolet detection was 
used (HP 110 Series System, Hewlett-Packard, Waldbronn, Germany) [15]. The 
level of Hcy was calculated using calibration standards. 
 
MTHFR (677C>T) polymorphism analysis 
To establish the relationship between the MTHFR (677C>T) polymorphism and 
MP formation, DNA was extracted from every cell of the primary culture using  
a NucleoSpin Blood Mini Kit (740 951.250 Macherey-Nagel, Düren, Germany). 
The genotyping of the MTHFR polymorphism was performed by real-time 
quantitative polymerase chain reaction (ABI PRISM® 7900HT Fast Real-Time 
PCR System, Applied Biosystems) using TaqMan Universal PCR Master Mix 
(Applied Biosystems): the wild allele (C)-complementary probe sequence 
conjugated with VIC fluorochrome and the mutant allele (T)-complementary 







The results are presented as the means ± SD. The data was analyzed by the 
Kruskal-Wallis test and the Mann-Whitney U test, using the Statistica 8.0 PL 





Hcy turnover in HUVEC culture 
The analysis of Hcy turnover in the cell culture supernatant showed that the 
concentrations of Hcy changed significantly after treatment with FA (Fig. 1). 
The mean concentration of Hcy in the presence of 50 μM of FA significantly 
decreased, from 48.14 ± 7.84 to 29.62 ± 7.93 μM (p = 0.03) after a 24-h 
incubation. Similarly, treatment with 5- and 15-μM doses of FA resulted in  




a reduction in the Hcy concentration: 54.43 ± 6.89 vs 34.84 ± 4.79 μM (p = 0.01); 
and 45.95 ± 7.22 vs 33.92 ± 8.71 μM (p = 0.03), respectively. Treatment with 
Met alone caused increases in the Hcy levels in the cell culture supernatant:  




Fig. 1. An analysis of the homocysteine concentrations in the cell culture supernatant after 
HUVEC incubation with homocysteine (Hcy), or Hcy and folic acid (FA) or with 
methionine (Met) alone. *p = 0.01, **p = 0.03, ***p = 0.001. The data is presented as the 




Fig. 2. The formation of microparticles (MPs) in HUVEC after stimulation with Hcy and 
Met with the presence of FA in the cell culture; *p = 0.02, **p = 0.03. The data is 
presented as the means ± SD. The number of MPs is standardized to one million cells per 
culture flask. 
 
The effect of Hcy and Met on MP formation in HUVEC 
The flow cytometry analysis showed that HUVEC formed MPs in vitro under 
the control conditions (Fig. 2). Stimulation of HUVEC with Hcy significantly 
induced MP formation  when compared to the control conditions: 3,551 ± 620 vs 
2,270 ± 657 kMP (p = 0.02). Moreover, supplementation with FA at 
concentrations of 5, 15 and 50 μM significantly reduced the MP count in the cell 
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culture supernatant: 345 ± 332; 873 ± 329; and 688 ± 453 kMP (p = 0.03), 
respectively. The protective effect of FA supplementation was also noticeable in 
presence of the moderate concentration of Hcy (50 μM): 376 ± 155 vs 670 ± 258 
vs 420 ± 193 kMP; p = 0.03. Interestingly, Met treatment did not increase MP 
formation in the HUVEC, compared to the result obtained under the control 
conditions (1,665 ± 439 vs 2,270 ± 657 kMP). The protective effect of FA on 
Hcy-stimulated MP formation was not dose-dependent, and no correlation 
between the FA concentrations and the MP number was observed: r = -0.4, p = 0.44. 
 
The MTHFR (677C>T) polymorphism and Hcy-induced MP formation in 
HUVEC 
The effect of the MTHFR polymorphism on MP formation was analyzed (Fig. 
3). Three of six cell lines analyzed were heterozygous for the 677C>T 
polymorphism and three were homozygous (677CC). The MTHFR genotype of 
the HUVEC altered MP formation after Met loading (50 μM): the heterozygotic 
(677C>T) HUVEC produced twice as many microparticles per million cells as 
the homozygotic (677CC) ones: 2,341 ± 1,027 vs 1,015 ± 103kMP (p = 0.001). 
Surprisingly, the MTHFR 677CC polymorphism did not alter the MP release 
under control conditions nor in the presence of Hcy (50 μM): p = 0.25 and p = 0.66, 
respectively (Fig. 3). A significant increase in MP formation after stimulation 
with Hcy compared to the results obtained under the control conditions was 
observed both in heterozygotic (677CT) and homozygotic (677CC) HUVEC: 
respectively, 1,518 ± 343 vs 2,617 ± 152  kMP (p = 0.02); and 2,982 ± 906 vs 




Fig. 3. The role of the MTHFR (677C>T) polymorphism in MP formation in HUVEC after 
stimulation with Hcy and Met with the presence of FA in the cell culture. *p = 0.03 and 
**p = 0.02 vs control conditions; ***p = 0.001 vs homozygote 677CC. The data is 









The role of Hcy in apoptotic MP formation 
Annexin V-positive MPs are a marker of apoptosis [10]. On average, 24% of the 
entire MP population was conjugated with annexin V. No difference in the level 
of MP formation was observed between stimulation with Hcy and Met (p = 0.15). 
Surprisingly, folate had no significant effect on the MP phenotype. Neither 
increasing concentrations of FA (p = 0.71) nor the presence of Hcy (p = 0.45) 
influenced the proportion of annexin V-positive MPs in the overall population of 




The formation of endothelial MPs is associated with a pathological state which 
may lead to tissue factor expression and procoagulant activity [11, 16]. Many 
studies suggest that endothelial cell-derived MPs have a paracrine role and 
contribute to the development of endothelial dysfunction in most cardiovascular 
diseases: CAD, MI, hypertension and congestive heart failure. Moreover, 
diabetes, end-stage renal failure and pulmonary or venous embolism are strong 
factors bringing about MP shedding [13, 14, 17].  
Our study demonstrated that in moderate concentrations, Hcy stimulates 
endothelial cells (HUVEC) to MP formation, and that FA prevents HUVEC from 
MP shedding. We may assume that the MTHFR polymorphism is related to MP 
formation in HHcy and methionine-loading conditions, and that endothelial cell-
derived MPs have a diverse phenotype, not only apoptotic. 
A possible relationship was previously demonstrated between hyperhomocysteinemia 
after an oral methionine load and endothelial function in healthy adults and 
cardiovascular patients [18]. Increased Hcy levels, which are related to ischemic 
conditions, share similar mechanisms that lead to MP formation as a result of 
cardiac ischemia, myocardial infarction  (MI) and stroke [9, 17, 19]. Moreover, 
endothelial MP numbers correlate inversely with the flow-mediated 
vasodilatation response and endothelial-related vasorelaxation [12, 20]. Our 
findings concur with those showing that circulating MPs promote the 
development of endothelial dysfunction. The different influences of free radicals 
on the inter- and intracellular mechanisms of bradykinin-dependent 
vasodilatation compared to vasodilatation in response to other endothelium-
dependent stimuli may be regulated by means of MP release [21]. 
Usui et al. [22] demonstrated that in healthy volunteers, methionine loading 
acutely attenuated endothelial functions. Pretreatment with FA did not prevent 
the rise in homocysteine levels, but prevented the impaired vascular response. 
Our study confirms that FA is an active protector against endothelial cell 
dysfunction. We demonstrated that FA prevents HUVEC from MP formation 
under the control conditions, and that this effect was maintained after stimulation 
with Hcy. Interestingly, folate activity was not dose-dependent in our model, and 
the concentrations used were efficient. We supposed that the MTHFR 
polymorphism is involved in MP formation in endothelial cells; the 
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heterozygotic HUVEC responded more significantly to methionine loading and 
produced twice as many MPs than homozygotic ones. Our study is in accordance 
with some previous reports on the role of familial hyperhomocysteinemia in 
atherosclerosis and endothelial dysfunction [11, 18]. Oral administration of 
methionine at a dose of 100 mg/kg is usually used to induce moderate 
hyperhomocysteinemia (~25 μM) in healthy human subjects [7]. In our study, 
we observed that in vitro administration of Met (50 μM) resulted in moderate 
concentrations of Hcy (33.42 ± 3.72 μM) in the culture supernatant, and these 
conditions induced a significant increase in the number of MPs. However, we 
did not observe a similar relationship in the presence of Hcy alone (50 μM). Our 
observation is in line with Den Heijer’s et al. study, which showed that the post-
load homocysteine levels had stronger genetic determination than the fasting 
homocysteine levels [23]. In addition, current data suggests that MP number 
may be genetically regulated [12]. 
In our study, most MPs were not annexin V-positive (about 75%), which may 
suggest that the apoptotic process does not dominate in the HHcy response [10]. 
Unlike other uremic toxins, Hcy did not influence an increase in apoptotic MP 
numbers [13]. We might speculate that non-apoptotic MPs have proangiogenic 
activity or transfer coagulation factors (i.e. tissue factors) [14, 16, 17].  
We did not analyze the detailed phenotype of HUVEC-derived MPs and this 
remains a subject for further study. The mechanism of MP formation after Hcy 
treatment is not clear, but we can postulate that endothelial cells can manage 
oxidative stress, and MP shedding is a physiological response to moderate 
hyperhomocysteinemia. We may conclude that the endothelial function 
impairment due to HHcy is related to MP shedding, which may involve platelets 
and other cells like monocytes or vascular cells. 
The limitations of our study are that we used CD31 as the sole marker for 
endothelial MPs, and that we did not include other markers of endothelial 
activation, e.g. tissue factor, E-cadheris or cell adhesion molecules. Secondly, we 
used a low number of different cell lines  and replicates in our experiments, but 
we may assume that in vitro conditions confirm our results. Thirdly, we did not 
take into consideration the 677TT genotype, which may have been helpful in 
confirming the role of Hcy metabolism in MP release. However, in certain cell 
types, an unfavourable phenotype might be driven directly by heterozygosity. 
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